Literature DB >> 3632917

Long-term follow-up of general immune competence in breast cancer. II. Sequential pre- and post-treatment levels: a 10 year study.

H S Shukla, L E Hughes, R H Whitehead, R G Newcombe.   

Abstract

Pre-treatment and sequential post-treatment (at 3 months, 6 months, 1, 2, 3, 4 and 5 years) examination of general immune competence was performed in 185 consecutive breast cancer patients. The patients were followed for 5 to 11 years to monitor the dynamic relationship between host immunity and cancer and to examine the effect of the treatment method. The tests of immune competence used were immunoglobulins IgG, IgA, IgM, leucocyte counts, percentage and total lymphocyte counts and Mantoux and DNCB skin hypersensitivity tests. Serum IgG and IgA showed no change relating to treatment method in recurrence-free patients; but IgG levels were higher when recurrent disease was imminent or established; IgM diminished (P less than 0.001) after treatment and this continued at 5 years in all patient groups. Simple lymphocyte counts showed the most interesting changes. They remained depressed for as long as 60 months following radiotherapy (P less than 0.01). After treatment by surgery, lymphocyte counts rose in patients without recurrence, but fell when systemic recurrence was imminent or established. This effect was not seen in patients with local recurrence only. There was no change in immune competence immediately before recurrence sufficient to be of clinical usefulness, but a low pre-treatment lymphocyte count with a steady rise after surgery carried a good prognosis. Similarly a high initial lymphocyte count with a fall after surgery was indicative of recurrence. Universal and prolonged depression of lymphocyte counts following radiotherapy was confirmed, and the effect was additive to that of tumour load in recurrent disease. Because of the large number of statistical calculations carried out, some of the apparently significant findings may be due to chance. However, the general trends emerging suggest that similar long-term studies, using the more sophisticated measures of lymphocyte function now available, might be rewarding.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3632917     DOI: 10.1007/BF00199370

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

1.  The curability of breast cancer.

Authors:  M Baum
Journal:  Br Med J       Date:  1976-02-21

2.  The cell cycle in tumours: an examination of data gained by the technique of labelled mitoses.

Authors:  G G Steel
Journal:  Cell Tissue Kinet       Date:  1972-01

3.  Pre-treatment general immune competence and prognosis in breast cancer. A prospective 2-year follow-up.

Authors:  C Teasdale; J W Hillyard; D J Webster; P M Bolton; L E Hughes
Journal:  Eur J Cancer       Date:  1979-07       Impact factor: 9.162

4.  Immunocompetence, immunosuppression, and human breast cancer. I. An analysis of their relationship by known parameters of cell-mediated immunity in well-defined clinical stages of disease.

Authors:  J A Stein; A Adler; S B Efraim; M Maor
Journal:  Cancer       Date:  1976-09       Impact factor: 6.860

5.  Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer.

Authors:  Y T Lee; F C Sparks; F R Eilber; D L Morton
Journal:  Cancer       Date:  1975-03       Impact factor: 6.860

6.  Immunobiology of operable breast cancer: an assessment of biologic risk by immunoparameters.

Authors:  H J Wanebo; P P Rosen; T Thaler; J A Urban; H F Oettgen
Journal:  Ann Surg       Date:  1976-09       Impact factor: 12.969

7.  T and B lymphocytes in breast cancer stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro.

Authors:  R H Whitehead; J Thatcher; C Teasdale; G P Roberts; L E Hughes
Journal:  Lancet       Date:  1976-02-14       Impact factor: 79.321

8.  Long-term (5-11 years) follow-up of general immune competence in breast cancer. I. Pre-treatment levels with reference to micrometastasis.

Authors:  H S Shukla; L E Hughes; R H Whitehead; R G Newcombe
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Prognostic relevance of immunologic variables in breast carcinoma.

Authors:  E Baral; H Blomgren; B Petrini; J Wasserman; S Ogenstad; C Silfverswärd
Journal:  Acta Radiol Ther Phys Biol       Date:  1977-10

10.  Prognostic value of peripheral lymphocyte count in hormone therapy of advanced breast cancer.

Authors:  C R Franks; Y Williams
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

View more
  3 in total

1.  Immune defects in breast cancer patients after radiotherapy.

Authors:  Leanna J Standish; Carolyn Torkelson; Frank A Hamill; Daesong Yim; Alicia Hill-Force; Annette Fitzpatrick; Monica Olsen; Sandi Schildt; Erin Sweet; Cynthia A Wenner; Mark R Martzen
Journal:  J Soc Integr Oncol       Date:  2008

2.  Long-term (5-11 years) follow-up of general immune competence in breast cancer. I. Pre-treatment levels with reference to micrometastasis.

Authors:  H S Shukla; L E Hughes; R H Whitehead; R G Newcombe
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Long-term changes in blood counts after intraoperative radiotherapy for breast cancer-single center experience and review of the literature.

Authors:  Cornelia Wersal; Anke Keller; Christel Weiss; Frank A Giordano; Yasser Abo-Madyan; Benjamin Tuschy; Marc Sütterlin; Frederik Wenz; Elena Sperk
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.